Mycolactone subverts immunity by selectively blocking the Sec61 translocon

Mycolactone, an immunosuppressive macrolide released by the human pathogen Mycobacterium ulcerans, was previously shown to impair Sec61-dependent protein translocation, but the underlying molecular mechanism was not identified. In this study, we show that mycolactone directly targets the alpha subunit of the Sec61 translocon to block the production of secreted and integral membrane proteins with high potency. We identify a single-amino acid mutation conferring resistance to mycolactone, which localizes its interaction site near the lumenal plug of Sec61 alpha. Quantitative proteomics reveals that during T cell activation, mycolactone-mediated Sec61 blockade affects a selective subset of secretory proteins including key signal-transmitting receptors and adhesion molecules. Expression of mutant Sec61 alpha in mycolactone-treated T cells rescued their homing potential and effector functions. Furthermore, when expressed in macrophages, the mycolactone-resistant mutant restored IFN-gamma receptor-mediated antimicrobial responses. Thus, our data provide definitive genetic evidence that Sec61 is the host receptor mediating the diverse immunomodulatory effects of mycolactone and identify Sec61 as a novel regulator of immune cell functions.Peer reviewe

Total synthesis of mycolactones A/B and targeted analogues towards the mechanistic study of Buruli ulcer

L’ulcère de Buruli est une maladie nécrotique de la peau présente dans plus de trente pays dans le monde, et affectant principalement le continent africain et l’Océanie. L’infection est due à Mycobacterium ulcerans (M. ulcerans), un micro-organisme qui sécrète une exotoxine appelée mycolactone, représentant le premier polycétide isolé d’un pathogène humain. La maladie est caractérisée par la formation progressive de lésions nécrotiques combinée à une absence de réponse immunitaire et de sensation de douleur ; la mycolactone est connue pour être directement impliquée dans ce mécanisme biologique. A ce jour, aucun traitement totalement performant et spécifique contre l’ulcère de Buruli n’a été développé, ce qui révèle le manque crucial de connaissances sur les mécanismes chimique et biologique. Dans ce contexte, le projet développé s’intéresse à l’élucidation du mécanisme d’action des mycolactones en utilisant la synthèse totale comme outil principal. Pour cela, notre équipe a mis au point une voie de synthèse modulaire permettant la préparation de la toxine naturelle et de ses différents analogues en vue de les tester biologiquement et d’affiner ainsi notre compréhension mécanistique de cette infection.Buruli ulcer is a necrotizing skin disease present in more than thirty countries in the world, located mainly in West and Central Africa but also in Australia and in Japan. This infection is caused by Mycobacterium ulcerans (M. ulcerans) that secretes a macrolide toxin called mycolactone, which is the first polyketide isolated from a human pathogen. The disease is characterized by the formation of painless progressive necrotic lesions combined with a lack of acute inflammatory response, and mycolactone is known to be directly involved in the biological mechanism. To date no specific and completely efficient treatment of Buruli ulcer has been developed which correlates with the dramatic lack of understanding of the associated chemical and biological mechanisms. In this context, this research project aims at a better understanding of mycolactone A/B molecular interactions by using total synthesis as main tool. To this end, our research team has developed an efficient synthetic pathway allowing the preparation of the natural toxin and its differents analogues for purposes of their biological evaluation and fine-tuning our mechanical understanding of this infection

Synthèse totale de mycolactone A/B et d'analogues ciblés pour l'étude mécanistique de l'ulcère de Buruli

Buruli ulcer is a necrotizing skin disease present in more than thirty countries in the world, located mainly in West and Central Africa but also in Australia and in Japan. This infection is caused by Mycobacterium ulcerans (M. ulcerans) that secretes a macrolide toxin called mycolactone, which is the first polyketide isolated from a human pathogen. The disease is characterized by the formation of painless progressive necrotic lesions combined with a lack of acute inflammatory response, and mycolactone is known to be directly involved in the biological mechanism. To date no specific and completely efficient treatment of Buruli ulcer has been developed which correlates with the dramatic lack of understanding of the associated chemical and biological mechanisms. In this context, this research project aims at a better understanding of mycolactone A/B molecular interactions by using total synthesis as main tool. To this end, our research team has developed an efficient synthetic pathway allowing the preparation of the natural toxin and its differents analogues for purposes of their biological evaluation and fine-tuning our mechanical understanding of this infection.L’ulcère de Buruli est une maladie nécrotique de la peau présente dans plus de trente pays dans le monde, et affectant principalement le continent africain et l’Océanie. L’infection est due à Mycobacterium ulcerans (M. ulcerans), un micro-organisme qui sécrète une exotoxine appelée mycolactone, représentant le premier polycétide isolé d’un pathogène humain. La maladie est caractérisée par la formation progressive de lésions nécrotiques combinée à une absence de réponse immunitaire et de sensation de douleur ; la mycolactone est connue pour être directement impliquée dans ce mécanisme biologique. A ce jour, aucun traitement totalement performant et spécifique contre l’ulcère de Buruli n’a été développé, ce qui révèle le manque crucial de connaissances sur les mécanismes chimique et biologique. Dans ce contexte, le projet développé s’intéresse à l’élucidation du mécanisme d’action des mycolactones en utilisant la synthèse totale comme outil principal. Pour cela, notre équipe a mis au point une voie de synthèse modulaire permettant la préparation de la toxine naturelle et de ses différents analogues en vue de les tester biologiquement et d’affiner ainsi notre compréhension mécanistique de cette infection

Total synthesis of mycolactones A/B and targeted analogues towards the mechanistic study of Buruli ulcer

L’ulcère de Buruli est une maladie nécrotique de la peau présente dans plus de trente pays dans le monde, et affectant principalement le continent africain et l’Océanie. L’infection est due à Mycobacterium ulcerans (M. ulcerans), un micro-organisme qui sécrète une exotoxine appelée mycolactone, représentant le premier polycétide isolé d’un pathogène humain. La maladie est caractérisée par la formation progressive de lésions nécrotiques combinée à une absence de réponse immunitaire et de sensation de douleur ; la mycolactone est connue pour être directement impliquée dans ce mécanisme biologique. A ce jour, aucun traitement totalement performant et spécifique contre l’ulcère de Buruli n’a été développé, ce qui révèle le manque crucial de connaissances sur les mécanismes chimique et biologique. Dans ce contexte, le projet développé s’intéresse à l’élucidation du mécanisme d’action des mycolactones en utilisant la synthèse totale comme outil principal. Pour cela, notre équipe a mis au point une voie de synthèse modulaire permettant la préparation de la toxine naturelle et de ses différents analogues en vue de les tester biologiquement et d’affiner ainsi notre compréhension mécanistique de cette infection.Buruli ulcer is a necrotizing skin disease present in more than thirty countries in the world, located mainly in West and Central Africa but also in Australia and in Japan. This infection is caused by Mycobacterium ulcerans (M. ulcerans) that secretes a macrolide toxin called mycolactone, which is the first polyketide isolated from a human pathogen. The disease is characterized by the formation of painless progressive necrotic lesions combined with a lack of acute inflammatory response, and mycolactone is known to be directly involved in the biological mechanism. To date no specific and completely efficient treatment of Buruli ulcer has been developed which correlates with the dramatic lack of understanding of the associated chemical and biological mechanisms. In this context, this research project aims at a better understanding of mycolactone A/B molecular interactions by using total synthesis as main tool. To this end, our research team has developed an efficient synthetic pathway allowing the preparation of the natural toxin and its differents analogues for purposes of their biological evaluation and fine-tuning our mechanical understanding of this infection

A Straightforward Entry to gamma-Trifluoromethylated Allenamides and their Synthetic Applications

gamma-Trifluoromethylated allenamides were obtained in good to excellent yields through a base-induced isomerization from the corresponding protected trifluoromethylated propargylic amines. The method, which simply required the treatment of the starting propargylic amines with sodium hydroxide in THF, was found to be fairly general and tolerates various alkyl and aryl substituents on the nitrogen atom and a range of protecting groups. The reactivity of the gamma-trifluoromethylated allenamides was explored and they were found to be excellent substrates for radical- and gold(I)-catalysed cyclizations yielding to fluoroalkylated nitrogen heterocycles.info:eu-repo/semantics/publishe

Total Syntheses of Mycolactone A/B and its Analogues for the Exploration of the Biology of Buruli Ulcer

Buruli ulcer, classified as a neglected tropical disease by the World Health Organization, is caused by a mycobacterium which secretes a macrolidic exotoxin called mycolactone A/B. In this article, several synthetic strategies for the preparation of this toxin are discussed, highlighting the importance of total synthesis for the exploration of biological mechanism underpinning relevant human diseases

Modular total syntheses of mycolactone A/B and its [ 2 H]- isotopologue

International audienceA modular total synthesis of mycolactone A/B, the exotoxin produced by Mycobacterium ulcerans has been achieved through the orchestration of several Pd-catalyzed key steps. While this route leads to a mixture of the natural product and its C12 epimer (4:1 ratio), this was inconsequential from the biological activity standpoint. Compared to previously reported routes, this synthetic blueprint allows the late-stage modification of the toxin, as exemplified with the preparation of [22,22,22-

2 H-1,2,3-Triazole-based dipeptidyl nitriles : potent, selective, and Trypanocidal rhodesain inhibitors by structure-based design

Macrocyclic inhibitors of rhodesain (RD), a parasitic cysteine protease and drug target for the treatment of human African trypanosomiasis, have shown low metabolic stability at the macrocyclic ether bridge. A series of acyclic dipeptidyl nitriles was developed using structure-based design (PDB ID: 6EX8 ). The selectivity against the closely related cysteine protease human cathepsin L (hCatL) was substantially improved, up to 507-fold. In the S2 pocket, 3,4-dichlorophenylalanine residues provided high trypanocidal activities. In the S3 pocket, aromatic residues provided enhanced selectivity against hCatL. RD inhibition ( K; i; values) and in vitro cell-growth of Trypanosoma brucei rhodesiense (IC; 50; values) were measured in the nanomolar range. Triazole-based ligands, obtained by a safe, gram-scale flow production of ethyl 1 H-1,2,3-triazole-4-carboxylate, showed excellent metabolic stability in human liver microsomes and in vivo half-lives of up to 1.53 h in mice. When orally administered to infected mice, parasitaemia was reduced but without complete removal of the parasites